Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Timothy Oh, Ari Pelcovits, Natalie Grover, Colin Thomas, Yun Kyoung Tiger, Matthew Cortese, James Davis, Adam Kidwell, Tamara Moyo, Lindsey Fitzgerald, Jonathon Cohen, Megan Melody, Nikesh Shah, Vaishalee Kenkre, Brian Hess, Thomas Ollila, Megan Herr, Geoffrey Shouse, Salmaan Mubeen, Omar Elghawy, Daniel Antonio, Daniel Kerr, Calvin Lee, Jonathan Moreira, Shuo Ma, Jane Winter, Nirav Shah, Leo Gordon, Narendranath Epperla, Deborah Stephens, Reem Karmali
Institutions: Northwestern University, Brown University, University of North Carolina at Chapel Hill, University of Pennsylvania, Rutgers, The State University of New Jersey, Rutgers Cancer Institute, Roswell Park Comprehensive Cancer Center, Medical University of South Carolina, MUSC Hollings Cancer Center, Medical College of Wisconsin, Medical College of Wisconsin Cancer Center, Levine Cancer Institute, University of Utah, Huntsman Cancer Institute, Emory University, Winship Cancer Institute, Tampa General Hospital, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, City Of Hope National Medical Center, City of Hope, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University at Buffalo, State University of New York, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417018418
Cites:
Cited by:
Related to: